Statement of Intention Not to Make Offer for York


 

TIDMYRK 
 
RNS Number : 3643W 
ULURU 
27 July 2009 
 

 
 
ULURU NEWS 
 
 
Contact: Company 
Renaat E. Van den Hooff 
President & CEO 
Terry K. Wallberg 
Vice President & CFO 
(214) 905-5145 
 
 
 
 
ULURU INC. 
STATEMENT OF INTENTION NOT TO MAKE AN OFFER FOR 
YORK PHARMA, PLC. 
 
 
 
Addison, Texas, July 27, 2009; ULURU Inc. (NYSE AMEX: ULU) today announced that, 
following repayment of all amounts owing to ULURU under the secured revolving 
credit facility established pursuant to that certain Note Purchase Agreement 
dated March 31, 2009 by and between ULURU and York Pharma plc ("York"), ULURU no 
longer intends to make a takeover offer for York. 
 
 
UK Takeover Code Requirements 
 
 
ULURU hereby confirms for the purposes of Rule 2.8 of the City Code on Takeovers 
and Mergers (the "City Code") that this announcement constitutes a statement of 
its intention not to make an offer for York. 
 
 
Under Rule 2.8 of the City Code, and except with the consent of the Takeover 
Panel, the statement in the preceding paragraph will prevent ULURU or anyone 
acting in concert with it from announcing an offer or possible offer for York or 
taking certain other action within the next six months unless there has occurred 
an event, as set out below, which enables the statement to be set aside. 
 
 
Accordingly, for the purposes of Rule 2.8 of the City Code, ULURU reserves the 
right (on behalf of itself and anyone acting in concert with it) to announce an 
offer or possible offer for York and/or to take any other action which would 
otherwise be restricted under Rule 2.8 of the City Code within the next six 
months in the event that: 
 
 
(i) the agreement or recommendation of the board of York is given to the making 
of such an announcement or the taking of any such other action; or 
 
 
(ii) a third party announces an offer or a possible offer for York; or 
 
 
(iii) York announces a 'whitewash proposal' or a 'reverse takeover' (each as 
defined in the City Code). 
 
 
About ULURU Inc.: 
ULURU Inc. is a specialty pharmaceutical company focused on the development of a 
portfolio of wound management and oral care products to provide patients and 
consumers with improved clinical outcomes through controlled delivery utilizing 
its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal 
delivery system.  For more information about ULURU Inc., please visit 
www.uluruinc.com.  For more information about Altrazeal(TM), please visit 
www.Altrazeal(TM).com. 
 
 
This press release contains certain statements that are forward-looking within 
the meaning of Section 27a of the Securities Act of 1933, as amended, including 
statements relating to the possible acquisition of York by the Company and 
statements relating to potential strategic benefits of any such acquisition. 
These statements are subject to numerous risks and uncertainties, including but 
not limited to the risk factors detailed in the Company's Annual Report on Form 
10-K for the year ended December 31, 2008 and other reports filed by us with the 
Securities and Exchange Commission. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 STRILFVADIIDFIA

York Pharma (LSE:YRK)
過去株価チャート
から 5 2024 まで 6 2024